Walgreens On Tuesday, the financial profit and revenue reported in the second quarter, which fulfilled the expectations because the giant in retail, the Riese Riese Riese Riese giant, benefited and prepare for becoming private.
The company is privately taken by Sycamore partners in a contract of around 10 billion US dollars, which is expected to be concluded in the fourth quarter of this year. In view of the pending transaction, Walgreens pulled back his fiscal 2025 instructions. In January it expects an adjusted profit of $ 1.40 to $ 1.80 per share.
The historical deal with Sycamore ends the turbulent run from Walgreens as a stock corporation, which began in 1927. The company switches shops and lowers different costs CVFood and retail chains and Amazon. It is also used with a restless increase in health care.
The shares of Walgreens rose by almost 2%on Tuesday in the Premarket trade.
The following reported Walgreens for the three -month period, which ended on February 28, compared to the expectations of Wall Street, based on a survey of LSEG analysts:
- Win each share: 63 cents are expected compared to 53 cents
- Revenue: 38.59 billion US dollars expected compared to $ 38 billion
“The results in the second quarter reflect disciplined cost management and improvement in US health care, some of which were compensated for by weaker front-end results in the US retail pharmacy, while considerable legal settlements led to another negative free cash flow,” said Tim Wentworth, CEO of Walgreens, in a release.
“We remain in the early phases of our turning plan and continue to expect a sensible added value to take up time, focus and bring the focus and balance of future cash needs with the necessary investments for navigation in a changing pharmacy and a retail landscape,” he added.
During the second quarter of the financial year, Walgreens booked sales of US dollar sales of 4.1% compared to the same period last year, since sales in the US trading business and international segments increase.
The company reported a net loss of 2.85 billion US dollars or $ 3.30 per share in the second quarter. It is $ 5.91 billion or $ 6.85 per share compared to a net loss of $ 5.91.
With the exception of certain items, the adjusted profit was 63 cents per share for the quarter.
The results include a fee of $ 4.2 billion in connection with a loss of value of its US retail pharmacy and investments in the Villagemdirt of the Primary Care Clinic Chain.
However, Walgreens made a profit of $ 1 billion by pronouncing some of his shares in Cencora, an organization for pharmaceutical solutions, early and gaining his investments in Brightpring, a provider of comprehensive health services. These are two of the best investments from Walgreens.
The company's operational cash flow in the second quarter was affected by $ 969 million in legal payments for opioid-related settlements and a dispute with the Virtual Care Company Everh Solutions, which claimed that Walgreens broke the conditions of a business contract during the Covid 19 pandemy.
Comments are closed.